Top Banner
Sheep scab - developing resistance Sian Mitchell BVMS, PhD, Dip EVPC, Dip ECSRHM, MRCVS APHA Carmarthen Veterinary Investigation Centre and APHA Centre of Expertise in Extensively Managed Livestock
21

Sheep Scab Presentation - GOV.UK

Feb 10, 2022

Download

Documents

dariahiddleston
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Sheep Scab Presentation - GOV.UK

Sheep scab - developing resistanceSian Mitchell

BVMS, PhD, Dip EVPC, Dip ECSRHM, MRCVS

APHA Carmarthen Veterinary Investigation Centre and APHA Centre of Expertise in Extensively Managed Livestock

Page 2: Sheep Scab Presentation - GOV.UK

Sheep scab- developing resistance

• Clinical signs of sheep scab

• Treatments available

• Clinical case details winter 2016/17

• The in-vitro test developed at University of Bristol

• Further work

Page 3: Sheep Scab Presentation - GOV.UK

Clinical signs- pruritic (itchy) sheep

Page 4: Sheep Scab Presentation - GOV.UK

A typical case of sheep scab

Page 5: Sheep Scab Presentation - GOV.UK

Skin lesions and the mites

Page 6: Sheep Scab Presentation - GOV.UK

Sheep disease surveillance dashboardhttps://public.tableau.com/profile/siu.apha#!/vizhome/SheepDashboard_/SheepDashboard

Page 7: Sheep Scab Presentation - GOV.UK

Treatments

Only two types of treatment

• Injectable macrocyclic lactones (MLs) - ivermectin, doramectin, moxidectin

• Organophosphate (OP) dips

AND all of the group have to be treated

Page 8: Sheep Scab Presentation - GOV.UK

Injectable MLs

• Do not kill all mite stages immediately

• Site, method and ease of injection varies

• Varying persistency, so vary in need to move post treatment and time allowed before mixing with untreated sheep

• All are anthelmintics – use has implications on anthelmintic resistance development

Page 9: Sheep Scab Presentation - GOV.UK

OP dips

• Needs to be done correctly – immersion times, replenishment

Advantages

• Wash effect

• Broad spectrum ectoparasiticide (i.e. lice and mites)

Disadvantages

• Dip disposal

• Not licensed for use in showers

• Human health concerns

Page 10: Sheep Scab Presentation - GOV.UK

Clinical case 1

Large sheep flock in Ceredigion

October 2016 -Treatment with moxidectin 2% all ewes in different groups

November 2016. Number showing pruritis, one group 400 particularly badly affected. Repeated moxidectin 2%, no improvement

Mite samples to University of Bristol for in-vitro test development

OP dip - instant improvement

Page 11: Sheep Scab Presentation - GOV.UK

Clinical case 2

Sheep flock in Carmarthenshire

End October 2016 -Treatment of all animals with doramectin. Ewe lambs sent away ‘on tack’. No contact with other sheep, double fenced from neighbours

December 2016. Number showing pruritis, (particularly store lambs). PVS detected live Psoroptes ovis mites. Two injections of ivermectin given (meat withdrawal).

January 2017 Pruritis in number of animals, samples to APHA. Live mites in samples from two separate groups

Mite samples to University of Bristol

OP dip - all improved

Page 12: Sheep Scab Presentation - GOV.UK

Other cases, no in-vitro tests carried out

Sheep flock in mid Wales. Doramectin given twice to whole flock. Clinical signs persisted in animals in various groups. Samples to APHA. Live mites in all groups. OP dipping advised

Sheep flock Cheshire. Treated twice with doramectin October and November 2016. December, live mites seen in samples to veterinary practice. Weighed and treated moxidectin 2%. Little improvement.APHA samples, live mites seen. Dipped- all improved

Small sheep flock Shropshire. October 2016 all flock given doramectin, some clinical improvement. December 2016 Moxidectin 2%given, slight improvement. Jan 2017 doramectin used, no improvement. APHA samples Feb 2017 live mites seen- OP dip advised

Page 13: Sheep Scab Presentation - GOV.UK

Summary of cases

• Use of multiple ML treatments in each flock

• Often no diagnosis before first treatments

• Some cases showed slight clinical improvement post treatment, others no cessation of clinical signs

• Appeared that treatments had been done correctly

Page 14: Sheep Scab Presentation - GOV.UK

In-vitro test at University of Bristol

• Bioassay based on published method for resistance in Sarcoptes scabei mites (Brimer et al, Vet Parasitol (1995) 59, 249-255)

• Agar plates containing various concentrations of moxidectin and negative control plates. Mite mortality measured over time

• Psoroptes ovis mites from Moredun Research Institute (fully susceptible) used as controls

• Mortality from four field samples (two from Wales and two from Herefordshire) differed significantly from controls

• First demonstration of resistance in Psoroptes ovis mites to MLs in UK

• Likely cross resistance to other ML treatments

• Published Veterinary Record Jan 2018, 182 (4) 106

• Anecdotal evidence of other cases during winter 2016/17 and 17/18

Page 15: Sheep Scab Presentation - GOV.UK

0

20

40

60

80

100

0 24 72 96 120

Mo

rta

lity

(%

)

Time (h)

Negative control (MRI-)

ethanol only

Positive control (MRI+)

– 500 ng/ml moxidectin

Moredun Research Institute mites- controls

In-vitro bioassay 500 ng/ml moxidectin and ethanol control

Page 16: Sheep Scab Presentation - GOV.UK

0

20

40

60

80

100

0 24 72 96 120

Mo

rta

lity

(%

)

Time (h)

Negative control (MRI-)

ethanol only

Positive control (MRI+)

500 ng/ml

Farm outbreaks

West Wales & Welsh border)

(500 ng/ml moxidectin)

In-vitro bioassay results - 3 farms500 ng/ml moxidectin and controls

Page 17: Sheep Scab Presentation - GOV.UK

0

20

40

60

80

100

0 24 72 96 120

Mo

rta

lity

(%

)

Time (h)

Negative control (MRI-)

ethanol only

Moredun Research Institute control mites

Positive controls (MRI+)

●1000 ng/ml moxidectin

♦ 2000 ng/ml moxidectin

In-vitro bioassay 1000 and 2000ng/ml moxidectin and ethanol control

Page 18: Sheep Scab Presentation - GOV.UK

0

20

40

60

80

100

0 24 72 96 120

Mo

rta

lity

(%

)

Time (h)

Negative control (MRI-)

ethanol only

Positive controls (MRI+)

●1000 ng/ml moxidectin

♦ 2000 ng/ml moxidectin

Farm outbreak

(Herefordshire)

●1000 ng/ml moxidectin

♦ 2000 ng/ml moxidectin

In-vitro bioassay results - one farm1000 and 2000 ng/ml moxidectin and controls

Page 19: Sheep Scab Presentation - GOV.UK

Further work at University of Bristol 2017/18

• Testing more field samples

• Extending in vitro tests to using ivermectin and doramectin

Page 20: Sheep Scab Presentation - GOV.UK

Summary

• Diagnose, treat correctly and investigate poor clinical efficacy

• Free ectoparasite examination in Wales (ended 31st March 2018)

• Sheep scab is a severe welfare issue and causes production loss

• ML resistance will make sheep scab more difficult to control

Page 21: Sheep Scab Presentation - GOV.UK

Acknowledgements

• Practising vets and farmers for sample submission

• Prof Richard Wall, Emma Doherty and Charlotte Sturgess-Osborne, University of Bristol

• Dr Stewart Burgess, Moredun Research Institute

• University of Bristol work funded by Zoetis

• APHA scanning surveillance funded by Defra, Welsh and Scottish governments